Jco precision oncology.

DOI: 10.1200/PO.22.00317 JCO Precision Oncology no. 7 (2023) e2200317. Published online April 26, 2023. PMID: 37099733. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis ...22 Aug 2023 ... Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict ...PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N = 254). This exploratory analysis evaluates the association between prespecified molecular biomarkers and clinical outcomes. METHODS Cohort A ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of …Jun 27, 2017 · Purpose Multiple-gene, next-generation sequencing panels are increasingly used to assess hereditary cancer risks of patients with diverse personal and family cancer histories. The magnitude of breast and ovarian cancer risk associated with many clinically tested genes, and independent of family cancer history, remains to be quantified. Methods We queried a commercial laboratory database of ...

DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and …Web

JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...DOI: 10.1200/PO.21.00122 JCO Precision Oncology no. 5 (2021) 1354-1376. Published online August 25, 2021. Published online August 25, 2021. Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns

When it comes to precision cutting, having the right tool can make all the difference. That’s where the Super Cutter comes in. This innovative tool is designed to provide unparalleled accuracy and precision, making it a must-have for any DI...DOI: 10.1200/PO.20.00069 JCO Precision Oncology no. 4 (2020) 665-679. Published online June 16, 2020. Published online June 16, 2020. BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian CancerLimit abstract length to 275 words. Limit body text to 3,000 words (excluding the title page, abstract, references, figures, and tables). Limit of 6 total figures and tables, not including figure pieces. Table pieces (such as Table 1a and 1b) are not allowed. Include a CONSORT diagram for studies in which two or more groups are compared. JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.

PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS We conducted a retrospective multicenter study to identify patients with advanced prostate cancer who harbored somatic loss-of-function CDK12 ...

For this reason, JCO Precision Oncology has organized this special series of tutorial and review articles on statistical methods for precision oncology that will serve as a bridge between the clinical researcher and statistician communities, will help facilitate the application of new methods, and will stimulate the development of more and ...

Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ...Jul 28, 2020 · PURPOSE The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS In a 2 ... Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.Purpose Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers …DOI: 10.1200/PO.22.00197 JCO Precision Oncology no. 6 (2022) e2200197. Published online September 15, 2022. PMID: 36108259. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy ...DOI: 10.1200/PO.18.00037 JCO Precision Oncology - published online July 23, 2018WebFeb 16, 2022 · The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...

29 Sept 2022 ... Precision medicine in pediatric oncology. ... Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis ...DOI: 10.1200/PO.22.00715 JCO Precision Oncology no. 7 (2023) e2200715. Published online June 7, 2023. PMID: 37285561. Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer Sarah N. Gibbs, MPH 1. x. Sarah N. Gibbs. Search for articles by this author ...WebBy choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 insertion mutations are emerging as a distinct molecular subtype with expanding therapeutic options. We describe the molecular epidemiology and genomic features of HER2-altered NSCLC in an Asian tertiary cancer center. METHODS ...The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor gene sequencing panels have made this a challenging time for ...PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...

DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019PURPOSE With the introduction of precision medicine, treatment options for non–small-cell lung cancer have improved dramatically; however, underutilization, especially in disadvantaged patients, like those living in rural Appalachian regions, is associated with poorer survival. Molecular tumor boards (MTBs) represent a strategy to increase precision medicine use. UK HealthCare at the ...

DOI: 10.1200/PO.19.00032 JCO Precision Oncology - published online October 24, 2019DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017May 18, 2021 · As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ... DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and …WebLimit the abstract to 275 words and place it after the title page. Do not use proprietary or trade names in the title or abstract. Case Reports, Commentaries, Editorials, and Correspondence articles do not require abstracts. Write the body of the manuscript as concisely as possible. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …If you’ve scheduled an appointment at Alberta Precision Labs, you’re taking a proactive step towards managing your health. Whether it’s for routine blood work or a specific test, it’s important to prepare for your appointment to ensure the ...DOI: 10.1200/PO.20.00280 JCO Precision Oncology no. 5 (2021) 215-226. Published online January 19, 2021. PMID: 34994597. Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) ...WebThe American Society of Clinical Oncology explains that the end stage of cancer is diagnosed when the cancer has spread to other parts of the body. This stage is also called stage 4, advanced or metastatic cancer.DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report

DOI: 10.1200/PO.21.00108 JCO Precision Oncology no. 5 (2021) 1151-1159. Published online July 15, 2021. Published online July 15, 2021. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis

Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...

This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: MolecularMatch, Lutris, Iylon, Frontier Medicines.WebThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Genome Medical. Consulting or Advisory Role: Invitae, Genome Medical, Promega, 23andMe. David Cohn. Consulting or Advisory Role: …DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 AlterationsWebThe Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …DOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy詳細. タイトル. JCO precision oncology. JCO precision oncology. ... American Society of Clinical Oncology, publisher. ... Began with February 22, 2017. Began with ...Purpose Appendiceal neoplasms are heterogeneous and are often treated with chemotherapy similarly to colorectal cancer (CRC). Genomic profiling was performed on 703 appendiceal cancer specimens to compare the mutation profiles of appendiceal subtypes to CRC and other cancers, with the ultimate aim to identify potential biomarkers …JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebDOI: 10.1200/PO.20.00438 JCO Precision Oncology no. 5 (2021) 1659-1665. Published online October 27, 2021. Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma Arlet M. Acanda De La Rocha, PhD 1. x. Arlet M. Acanda De La Rocha. Search for articles by this author ...JCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other …As significant efforts in distinct geographical areas are underway to enhance the clinical impact of precision oncology, several challenges remain. First, the type of tumor sample used can affect the results of genomic assays and have downstream effects on therapeutic decisions. In a study comparing mutation calls from whole-exome sequencing in ...

DOI: 10.1200/PO.18.00028 JCO Precision Oncology - published online October 19, 2018WebThe analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ... May 11, 2022 · DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728 Instagram:https://instagram. curlf stock pricewhat is a good platform for day tradinghow to purchase heliumgood day trading platforms Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019 1921 liberty silver dollar coin valueappmail DOI: 10.1200/PO.21.00510 JCO Precision Oncology no. 6 (2022) e2100510. Published online June 8, 2022. PMID: 35675577. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures Kabir Mody, MD 1. x. Kabir Mody. Search for articles by this author; ...WebJCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and … uncirculated coins vs circulated Drug-related pneumonitis as a result of novel cancer therapy provides new challenges for providers of cancer care in the era of precision medicine. Awareness of this emerging entity and knowledge of its manifestations and management guidelines are essential for state-of-the-art practice of clinical oncology. Here, we provide a detailed …Oct 31, 2022 · PURPOSE To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting and interpretation of clinically relevant genomics data (ESMO Scale of Actionability of molecular Targets [ESCAT]). This study aims to characterize the clinical impact of matching targetable ... Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017